Get the Stockscreener App
40.75
1.21%
-0.50
After Hours:
40.75
Crinetics Pharmaceuticals Inc stock is traded at $40.75, with a volume of 916.83K.
It is down -1.21% in the last 24 hours and up +9.45% over the past month.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
See More
Previous Close:
$41.25
Open:
$41.51
24h Volume:
916.83K
Relative Volume:
0.83
Market Cap:
$4.30B
Revenue:
$7.70M
Net Income/Loss:
$-465.32M
P/E Ratio:
-8.2413
EPS:
-4.9446
Net Cash Flow:
$-383.68M
1W Performance:
+6.82%
1M Performance:
+9.45%
6M Performance:
-4.19%
1Y Performance:
+21.10%
1-Day Range:
$40.06
$42.47
1-Week Range:
$37.35
$42.47
52-Week Range:
$25.83
$57.99
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Name
Crinetics Pharmaceuticals Inc
Sector
Industry
Phone
858-450-6464
Address
6055 LUSK BLVD., SAN DIEGO, CA
Compare CRNX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
40.75 | 4.35B | 7.70M | -465.32M | -383.68M | -4.9446 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-26 | Upgrade | Goldman | Neutral → Buy |
| Jul-10-25 | Initiated | Goldman | Neutral |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-11-25 | Initiated | TD Cowen | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Peer Perform |
| Jan-22-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Jan-16-24 | Initiated | Morgan Stanley | Overweight |
| Dec-21-23 | Initiated | Jefferies | Hold |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-31-23 | Initiated | Oppenheimer | Outperform |
| Apr-24-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Robert W. Baird | Outperform |
| Nov-30-21 | Initiated | JMP Securities | Mkt Outperform |
| Nov-23-21 | Initiated | Evercore ISI | Outperform |
| Jun-18-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-23-19 | Initiated | ROTH Capital | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Aug-13-18 | Initiated | JP Morgan | Neutral |
| Aug-13-18 | Initiated | Leerink Partners | Outperform |
| Aug-13-18 | Initiated | Piper Jaffray | Overweight |
View All
Crinetics Pharmaceuticals Inc Stock (CRNX) Latest News
Technical Reactions to CRNX Trends in Macro Strategies - Stock Traders Daily
[144] Crinetics Pharmaceuticals, Inc. SEC Filing - Stock Titan
The Bull Case For Crinetics Pharmaceuticals (CRNX) Could Change Following EU Nod For Oral Acromegaly Drug PALSONIFY - Yahoo Finance
Analysts estimate Crinetics Pharmaceuticals, Inc. (CRNX) to report a decline in earnings: What to look out for - MSN
Crinetics Pharmaceuticals (CRNX): Billionaire Tom Steyer Likes This Pharma Stock - Insider Monkey
Crinetics Pharmaceuticals Inc (HAM:6Z4) Valuation: Possible Value Trap, Think Twice - GuruFocus
Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Weekly Buzz: FDA Okays Saphnelo Pen, EC Clears Acromegaly Drug, SNGX Slumps, LGND Snaps Up XOMA - RTTNews
Crinetics Pharmaceuticals (CRNX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Crinetics Pharmaceuticals Inc Stock Intrinsic Values | HAM:6Z4 - GuruFocus
Q3 2024 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q2 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Crinetics Pharmaceuticals Inc Stock Historical Valuations - GuruFocus
Q4 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q3 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q1 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Crinetics Pharmaceuticals Inc Stock Warning Signs - GuruFocus
Crinetics Pharmaceuticals Inc (HAM:6Z4) Stock Earnings Transcripts - GuruFocus
Crinetics Pharmaceuticals Inc (HAM:6Z4)Valuation Measures & Financial Statistics - GuruFocus
Crinetics Pharmaceuticals Inc (HAM:6Z4) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Crinetics Pharmaceuticals Inc Stock Baskets - GuruFocus
Crinetics Pharmaceuticals Inc (HAM:6Z4) Stock News, Headlines & Updates - GuruFocus
Crinetics Pharmaceuticals Inc (HAM:6Z4) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Who's Buying or Selling Crinetics Pharmaceuticals Inc (HAM:6Z4) Stock Today? - GuruFocus
Crinetics Pharmaceuticals Inc (HAM:6Z4) Stock Price, Trades & News - GuruFocus
Crinetics Pharmaceuticals Inc (HAM:6Z4) Stock Price & 30 Year Financial Data - GuruFocus
Crinetics Pharmaceuticals Inc Stock Operating Data - GuruFocus
Crinetics Pharmaceuticals Inc (HAM:6Z4) Dividend - GuruFocus
Vanguard Capital Management holds 5.19% of Crinetics (NASDAQ: CRNX) - Stock Titan
Crinetics (NASDAQ: CRNX) details 2026 meeting, board votes and auditor change - Stock Titan
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B - MSN
Crinetics Pharmaceuticals Files Marketing Application for Acromegaly Drug in Brazil - HarianBasis.co
Crinetics Pharmaceuticals (CRNX) is One of the Best Biotech Stocks to Buy, Here is Why - Insider Monkey
Q1 Earnings Estimate for CRNX Issued By Lifesci Capital - MarketBeat
Pictet Asset Management Holding SA Has $72.63 Million Stock Holdings in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
5 Best Biotech Stocks with Highest Upside Potential - Insider Monkey
CRNX Maintains Market Outperform Rating -- Price Target Raised t - GuruFocus
Crinetics Pharmaceuticals (NASDAQ:CRNX) Given New $97.00 Price Target at Citizens Jmp - MarketBeat
Citizens raises Crinetics stock price target on EU drug approval By Investing.com - Investing.com Canada
Crinetics receives EU approval for acromegaly drug Palsonify By Investing.com - Investing.com India
Crinetics (CRNX) Secures EU Approval for Palsonify in Acromegaly Treatment - GuruFocus
Crinetics receives EU approval for acromegaly drug Palsonify - Investing.com UK
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults - The Manila Times
Crinetics Pharmaceuticals Announces the European Commission - GlobeNewswire
Impax Asset Management Group plc Buys Shares of 275,000 Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
A Look At Crinetics Pharmaceuticals (CRNX) Valuation After Mixed Recent Share Performance - Sahm
Trading the Move, Not the Narrative: (CRNX) Edition - Stock Traders Daily
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
CRNX Stock Price, Quote & Chart | CRINETICS PHARMACEUTICALS IN (NASDAQ:CRNX) - ChartMill
Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer - GlobeNewswire Inc.
Crinetics (CRNX) Stock: Trading Guide (Range-Bound) 2026-04-15Stock Trading Network - Cổng thông tin điện tử tỉnh Tây Ninh
Crinetics Pharmaceuticals Inc Stock (CRNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):